3-Thia-4-arylquinolin-2-one derivatives as smooth muscle relaxants
AssigneeBristol-Myers Squibb Company
InventorKenneth M. Boy
Life of this patent
Estimating the term…
Abstract
This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome.
Drawings
Claims8
A compound of formula (I)
wherein:
R and R1 are independently hydrogen or methyl;
R2, R3, and R4 are independently hydrogen, halogen, cyano, nitro, or trifluoromethyl, provided R2, R3, and R4 are not all hydrogen;
R5 is bromo, chloro, or nitro;
R6 and R7 are independently hydrogen, C1-6 alkyl, C1-6 alkenyl, C3-7 cycloalkyl, —CH2C3-7 cycloalkyl, —(CH2)1-3OH, —(CH2)2-3NR8R9, —(CH2)1-3CN, or —(CH2)1-3Ar, where Ar is selected from the group consisting of phenyl, naphthyl, furanyl, thienyl, and pyridyl, and Ar is unsubstituted or substituted with 1–2 methoxy substituents;
or
NR6R7 taken together form
or
NR6R7 taken together are selected from the group consisting of
R8 and R9 are independently hydrogen or C1-6alkyl;
R10 is a bond, O, S, NR11, or CHR12;
R11 is hydrogen, C1-6 alkyl, CHO, C(O)Me, —(CH2)2-3OH, —CH2CH2OCH2CH2OH, —C(O)furanyl, or —CH2CH═CHPh;
R12 is hydrogen, hydroxy, C1-6 alkyl, —CH2Ph, —C(O)OR8, —(CH2)NR8R9, or 1-piperidinyl;
m is 0, 1, 2, or 3;
or a nontoxic pharmaceutically acceptable salt thereof.
10/964,078Filed 13 Oct 2004 · us provisional application
Priority
14 Oct 2003
Published
US 2005/0096329 A15 May 2005
Granted
21 Feb 2006
Term ended
29 Apr 2025Estimated · howhide20 years from earliest known nonprovisional domestic filing plus recorded patent term adjustment, including 198 days of adjustment. Maintenance-fee lapses, terminal disclaimers and statutory extensions have not been checked. The continuity chain may be incomplete; this is not an enforceability determination.
Containing two hetero rings: linked by a chain containing hetero atoms as chain links
Life of this patent
Term ended 29 Apr 2025 (estimated)
Priority14 Oct 2003
Granted21 Feb 2006
Term ended29 Apr 2025
Priority14 Oct 2003
Granted21 Feb 2006
Term ended29 Apr 2025
Priority claimedParent application 60/511,056
Application filedUS 10/964,078
Assigned to Bristol-Myers Squibb Companyassignment of assignor's interest
PublishedUS 2005/0096329 A1
GrantedUS 7,002,015 B2
Term endedEstimated, includes 198 days of adjustment
Description7,367 words
Summary688 words
#Potassium channels are transmembrane proteins which are ubiquitously expressed in mammalian cells and represent one of the largest and the most diverse group of ion channels from a molecular perspective. Potassium channels play a key role in regulation of cell membrane potential and modulation of cell excitability. Potassium channels are largely regulated by voltage, cell metabolism, calcium and receptor mediated processes. [Cook, N. S., Trends in Pharmacol. Sciences 1988, 9, 21; and Quast, U., et al., Trends in Pharmacol. Sciences 1989, 10, 431]. Calcium-activated potassium (KCa) channels are a diverse group of ion channels that share a dependence on intracellular calcium ions for activity. The activity of Kca channels is regulated by intracellular [Ca2+], membrane potential and phosphorylation. On the basis of their single-channel conductances in symmetrical K+ solutions, KCa channels are divided into three subclasses: large conductance (BK or Maxi-K) are those having a conductance of greater than about 150 picosemens (pS); intermediate conductance are those having a conductance of about 50–150 pS; and small conductance are those having a conductance of less than about 50 pS. Large-conductance calcium-activated potassium channels are present in many excitable cells including neurons, cardiac cells and various types of smooth muscle cells. [Singer, J. et al., Pflugers Archiv. 1987, 408, 98; Baro, I., et al., Pflugers Archiv. 1989, 414 (Suppl. 1), S168; and Ahmed, F. et al., Br. J. Pharmacol. 1984, 83, 227].
#Potassium ions play a dominant role in controlling the resting membrane potential in most excitable cells and maintain the transmembrane voltage near the K+ equilibrium potential (Ek) of about −90 millivolts (mV). It has been shown that opening of potassium channels shift the cell membrane potential towards the Ek, resulting in hyperpolarization of the cell. [Cook, N. S., Trends in Pharmacol. Sciences 1988, 9, 21]. Hyperpolarized cells show a reduced response to potentially damaging depolarizing stimuli. Those BK channels which are regulated by both voltage and intracellular Ca2+ act to limit depolarization and calcium entry and may be particularly effective in blocking damaging stimuli. Therefore cell hyperpolarization via opening of BK channels may result in protection of neuronal cells, as well as other types of cells, e.g., cardiac cells. [Xu, W., Liu, Y., Wang, S., McDonald, T., Van Eyk, J. E., Sidor, A., and O'Rourke, B. Cytoprotective Role of Ca2+-activated K+ Channels in the Cardiac Inner Mitochondrial Membrane. Science 2002, 298, 1029–1033].
#BK channels have been shown to be one of two physiologically relevant potassium channels in relaxing human smooth muscle, including both intestinal and penile smooth muscle. Evidence that relaxation of smooth muscle is beneficial to irritible bowel syndrome and erectile dysfunction has been reported. See the following references: Christ, G. J. Drug News Perspect. 2000, 13, 28–36; Poynard T. et al. Alimentary Pharmacology and Therapeutics 2001, 15, 355–361; and Argentieri, T. M. U.S. patent application Ser. No. 2002/0183395.
Detailed description6,679 words
#The present invention describes novel 3-thia-4-arylquinolin-2-one compounds and related derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof wherein: R and R1 are independently hydrogen or methyl; R2, R3, and R4 are independently hydrogen, halogen, cyano, nitro, or trifluoromethyl, provided R2, R3, and R4 are not all hydrogen; R5 is bromo, chloro, or nitro; R6 and R7 are independently hydrogen, C1-6 alkyl, C1-6 alkenyl, C3-7 cycloalkyl, —CH2C3-7 cycloalkyl, —(CH2)1-3OH, —(CH2)2-3NR8R9, —(CH2)1-3CN, or —(CH2)1-3Ar, where Ar is selected from the group consisting of phenyl, naphthyl, furanyl, thienyl, and pyridyl, and Ar is unsubstituted or substituted with 1–2 methoxy substituents; or NR6R7 taken together form or NR6R7 taken together are selected from the group consisting of R8 and R9 are independently hydrogen or C1-6alkyl; R10 is a bond, O, S, NR11, or CHR12; R11 is hydrogen, C1-6 alkyl, CHO, C(O)Me, —(CH2)2-3OH, —CH2CH2OCH2CH2OH, —C(O)furanyl, or —CH2CH═CHPh; R12 is hydrogen, hydroxy, C1-6 alkyl, —CH2Ph, —C(O)OR8, —(CH2)NR8R9, or 1-piperidinyl; and m is 0, 1, 2, or 3.
#The present invention also provides a method for the treatment or alleviation of disorders associated with BK channels, such as ischemia, stroke, convulsions, epilepsy, asthma, migraine, traumatic brain injury, spinal cord injury, sexual dysfunction, urinary incontinence and especially male erectile dysfunction and irritable bowel syndrome which comprises administering together with a conventional adjuvant, carrier or dilutent a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
#The term “atropisomer” refers to a stereoisomer resulting from restricted rotation about a single bond where the rotation barrier is high enough to permit isolation of the isomeric species.